Barclays reaffirmed their overweight rating on shares of bluebird bio (NASDAQ:BLUE) in a report published on Wednesday, MarketBeat reports. They currently have a $209.00 price target on the biotechnology company’s stock, up from their prior price target of $162.00.

A number of other research firms also recently commented on BLUE. Wells Fargo & Company reiterated an outperform rating and issued a $242.00 target price (up from $190.00) on shares of bluebird bio in a report on Tuesday. SunTrust Banks boosted their target price on shares of bluebird bio to $223.00 and gave the stock a buy rating in a report on Tuesday. Cantor Fitzgerald set a $113.00 target price on shares of bluebird bio and gave the stock an underweight rating in a report on Monday, December 11th. Jefferies Group upgraded shares of bluebird bio from a hold rating to a buy rating and boosted their target price for the stock from $130.00 to $211.00 in a report on Monday, December 11th. Finally, BMO Capital Markets set a $215.00 target price on shares of bluebird bio and gave the stock a buy rating in a report on Monday, December 11th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and thirteen have given a buy rating to the stock. The company currently has an average rating of Hold and an average price target of $157.45.

bluebird bio (NASDAQ BLUE) traded down $1.40 during mid-day trading on Wednesday, hitting $182.95. 1,719,045 shares of the company’s stock were exchanged, compared to its average volume of 1,086,152. bluebird bio has a one year low of $60.95 and a one year high of $222.03.

bluebird bio (NASDAQ:BLUE) last released its earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) EPS for the quarter, missing analysts’ consensus estimates of ($1.68) by ($0.05). bluebird bio had a negative return on equity of 28.79% and a negative net margin of 883.18%. The business had revenue of $7.71 million during the quarter, compared to the consensus estimate of $8.47 million. During the same quarter in the previous year, the firm earned ($2.07) earnings per share. The firm’s revenue for the quarter was up 397.4% compared to the same quarter last year. sell-side analysts anticipate that bluebird bio will post -6.72 earnings per share for the current fiscal year.

In related news, COO Susanna Gatti High sold 1,282 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $172.15, for a total transaction of $220,696.30. Following the transaction, the chief operating officer now directly owns 13,718 shares of the company’s stock, valued at $2,361,553.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mark Vachon sold 7,000 shares of the business’s stock in a transaction that occurred on Monday, December 11th. The shares were sold at an average price of $216.64, for a total transaction of $1,516,480.00. Following the transaction, the director now directly owns 8,000 shares in the company, valued at $1,733,120. The disclosure for this sale can be found here. Over the last three months, insiders sold 215,082 shares of company stock worth $37,227,332. 3.90% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in BLUE. QS Investors LLC grew its position in bluebird bio by 70.7% during the second quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 500 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. grew its position in bluebird bio by 454.2% during the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 992 shares of the biotechnology company’s stock valued at $136,000 after purchasing an additional 813 shares in the last quarter. Bank of Montreal Can grew its position in bluebird bio by 118.9% during the second quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock valued at $176,000 after purchasing an additional 911 shares in the last quarter. Turner Investments LLC purchased a new position in bluebird bio during the second quarter valued at approximately $184,000. Finally, Biondo Investment Advisors LLC purchased a new position in bluebird bio during the third quarter valued at approximately $203,000.

ILLEGAL ACTIVITY WARNING: “bluebird bio (BLUE) Earns Overweight Rating from Barclays” was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/bluebird-bio-blue-earns-overweight-rating-from-barclays/1768244.html.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with Analyst Ratings Network's FREE daily email newsletter.